NEW YORK, Dec. 03, 2015 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Valeant Pharmaceuticals International, Inc. (“Valeant Pharmaceuticals”) (NYSE:VRX) between February 23, 2015 and October 20, 2015.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey. To get more information go to:
http://zlk.9nl.com/valeant-pharmaceuticals
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that during the Class Period, defendants made false and misleading statements and/or failed to disclose adverse information about the Company’s business and prospects, including that: (a) the Company was using a network of specialty mail-order pharmacies that it actually controlled to prop up sales of its high-priced drugs and to keep patients and their insurance companies from switching to less costly generic drugs; (b) that Valeant's undisclosed use of specialty pharmacies left it subject to increased regulatory risks; and (c) that without the use of the specialty pharmacies, Valeant’s financial performance and Class Period financial guidance would have been negatively impacted. As a result of these false and misleading statements and/or omissions, Valeant stock traded at artificially inflated prices during the Class Period, reaching over $260 per share.
If you suffered a loss in Valeant Pharmaceuticals you have until December 21, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Washington Post Publisher Will Lewis Steps Down After Layoffs
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 



